Are there antibody-drug conjugates approved for Merkel Cell Carcinoma

Antibody-Drug Conjugates for Merkel Cell Carcinoma

Based on current NCCN Guidelines for Merkel Cell Carcinoma, there are no antibody-drug conjugates (ADCs) specifically approved as standard treatment options for MCC at this time.

What the Guidelines Show

According to the NCCN Guidelines Version 2.2026, the primary systemic treatment approaches for advanced or metastatic Merkel cell carcinoma focus on:

1. Immune checkpoint inhibitors (first-line):

   • Avelumab (FDA-approved)
   • Pembrolizumab (FDA-approved)
   • Nivolumab (FDA-approved)
   • Retifanlimab (FDA-approved)

2. Combination immunotherapy:

   • Nivolumab + ipilimumab (for PD-1 refractory disease)

3. Other approaches:

   • Chemotherapy (platinum-based regimens)
   • Talimogene laherparepvec (oncolytic virus therapy)
   • Somatostatin analogues (for patients with high somatostatin receptor expression)

Why This Matters

Antibody-drug conjugates are a different class of therapy—they combine antibodies (which target specific proteins on cancer cells) with chemotherapy drugs. While ADCs have shown promise in other cancers, MCC treatment has primarily advanced through immunotherapy rather than this approach.

Questions to Ask Your Oncologist

1. Are there any clinical trials testing ADCs for MCC that I might be eligible for?
2. Based on my specific tumor characteristics, which of the approved immunotherapies would you recommend?
3. If I become resistant to my current treatment, what are the next-line options?

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.